A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Uncontrolled, Severe Asthma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Jul 2017 Results of PK/PD model pooled data from two phase II studies published in the Clinical Pharmacology and Therapeutics
18 May 2016 Biomarker analysis results (healthy volunteers (N=20) and patients with asthma on ICS/LABA (N=68) or on ICS/LABA and OCS (N=22)), presented at the 112th International Conference of the American Thoracic Society
12 May 2014 According to an AstraZeneca media release, data from this trial will be presented at the American Thoracic Society (ATS) 2014, on 20 May 2014.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com